Mirikizumab is associated with rapid and sustained improvements in novel measures of bowel urgency in moderately-to-severely active ulcerative colitis: 28-week results from the LUCENT-URGE trial
- DOI
- 10.1093/ecco-jcc/jjag049
- Published
- 2026-05
- Container
- Journal of Crohn's and Colitis
- Publisher
- Oxford University Press (OUP)
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1093/ecco-jcc/jjag049,
title = {Mirikizumab is associated with rapid and sustained improvements in novel measures of bowel urgency in moderately-to-severely active ulcerative colitis: 28-week results from the LUCENT-URGE trial},
author = {Silvio Danese and Axel Dignass and David Laharie and Jimmy K Limdi and Radoslaw Kempinski and James D Lewis and Ziad Younes and Erica Cohen and Karla Alaka and William J Eastman and Tian Tian and Isabel Redondo and David T Rubin and Marla Dubinsky},
year = {2026},
journal = {Journal of Crohn's and Colitis},
doi = {10.1093/ecco-jcc/jjag049},
url = {https://doi.org/10.1093/ecco-jcc/jjag049}
}RIS
TY - JOUR TI - Mirikizumab is associated with rapid and sustained improvements in novel measures of bowel urgency in moderately-to-severely active ulcerative colitis: 28-week results from the LUCENT-URGE trial AU - Silvio Danese AU - Axel Dignass AU - David Laharie AU - Jimmy K Limdi AU - Radoslaw Kempinski AU - James D Lewis AU - Ziad Younes AU - Erica Cohen AU - Karla Alaka AU - William J Eastman AU - Tian Tian AU - Isabel Redondo AU - David T Rubin AU - Marla Dubinsky PY - 2026 JO - Journal of Crohn's and Colitis DO - 10.1093/ecco-jcc/jjag049 UR - https://doi.org/10.1093/ecco-jcc/jjag049 ER -
APA
Danese, S., Dignass, A., Laharie, D., Limdi, J. K., Kempinski, R., Lewis, J. D., Younes, Z., Cohen, E., Alaka, K., Eastman, W. J., Tian, T., Redondo, I., Rubin, D. T., & Dubinsky, M. (2026). Mirikizumab is associated with rapid and sustained improvements in novel measures of bowel urgency in moderately-to-severely active ulcerative colitis: 28-week results from the LUCENT-URGE trial. Journal of Crohn's and Colitis. https://doi.org/10.1093/ecco-jcc/jjag049
Source records
- crossref · retrieved 2026-11-10T12:55:19.736Z